Zinc for PCOS/PMOS: The Trial Behind the Hair Claims

The PCOS zinc study behind the hair claims is under publisher investigation, and its symptom outcomes were added to the trial registry after publication.

That is a bigger problem than the small sample. Even if we take the reported numbers at face value, the hormone result is mixed, acne did not improve significantly, and the paper's 50 mg zinc dose creates a second problem. This is a research lead, not a reliable zinc treatment for PCOS/PMOS.

Why the trial is not a stable foundation

The trial registry does not tell the same story as the published paper.

The earliest accessible English registry revision is dated November 9, 2014, after the registry's stated intervention period had ended. It planned 60 participants and named nitric oxide and oxidative-stress markers as the outcomes. A September 2019 revision, more than three years after the paper was published, changed the sample to 48 and added free testosterone, DHEA, alopecia, and hirsutism as outcomes.

The paper also says both groups received metformin, gradually increased to 1,500 mg a day. The registry excluded antidiabetic medication in its earlier revision and insulin sensitizers in the later one. I cannot reconcile those descriptions into one verified study design.

Then, on February 28, 2020, the publisher added a notice saying its editors were investigating the article because concerns had been raised about the integrity of the clinical trial. It also reported an investigation by the Iranian National Committee for Ethics in Biomedical Research (Springer Nature). The live article still carries that notice as of September 2, 2026.

This is not a retraction, and none of these facts proves that every reported number is false. They do mean the paper cannot carry the same weight as an unflagged, prospectively registered trial. I would not hide that in a methodology note after presenting the results as settled.

What the paper reports

Jamilian and colleagues' 2016 paper describes 48 women aged 18 to 40 with PCOS/PMOS, randomized to zinc or placebo for eight weeks. It says both groups received metformin. The zinc group also received 220 mg of zinc sulfate containing 50 mg of elemental zinc, while the placebo group received starch.

• The modified Ferriman-Gallwey hirsutism score fell by an average of 1.71 points with zinc and 0.29 points with placebo.
• The paper reported improvement in its alopecia measure for 41.7% of the zinc group and 12.5% of the placebo group. It used a five-point clinical scale but did not identify the assessor, say how many women in each group had alopecia at the start, show how far their ratings moved, count hairs, or measure density.
• Acne was measured, and the study did not find a significant benefit.
• Free testosterone and DHEA did not change significantly between groups. An adjusted analysis for 17-hydroxyprogesterone favored zinc even though the unadjusted result did not, so the paper does not establish one clear, consistent hormone effect. DHT was not measured.

Those are reported signals, not results I would build a routine around. The symptom outcomes were added to the registry after publication, the design descriptions conflict, the publisher is investigating the trial's integrity, and the paper did not report what happened after supplementation stopped.

What the result means for your goal

If you are considering zinc for acne, the paper makes the sales pitch weaker, not stronger. Acne was tested and did not improve significantly. It does not supply a four-to-eight-week acne timeline.

If your goal is facial or body hair, the hirsutism score is a reason for a properly registered, larger, and longer trial. It is not evidence that most women will see a visible change or that the effect persists.

If your goal is scalp hair, the clinical-scale result is interesting but underspecified. “Alopecia” describes hair loss, not its cause. The paper does not prove regrowth, correct a zinc deficiency, or show that zinc treats female-pattern hair loss caused by PCOS/PMOS.

Cycles, ovulation, and fertility were not reported. Nothing in this trial lets us move the hair signal into those outcomes.

If your real decision is what to do about facial hair, acne, or scalp hair loss, our outcome-by-outcome guide to reducing androgens in women compares the evidence for the result you actually want to change.

Why I would not copy the 50 mg dose

The paper reports 50 mg of elemental zinc a day. Elemental zinc is the zinc itself; the larger 220 mg number includes the sulfate attached to it.

For comparison, the NIH Office of Dietary Supplements sets the Recommended Dietary Allowance for an adult woman at 8 mg a day and the adult tolerable upper intake level at 40 mg a day from all sources. It notes that taking 50 mg or more for weeks can interfere with copper absorption, reduce immune function, and lower HDL cholesterol (NIH ODS).

The upper limit is not a treatment target, and 41 mg is not a magic toxicity switch. Clinicians sometimes have reasons to use an amount above it. But the study's 50 mg supplement already crossed that limit before zinc from food, a multivitamin, a prenatal, lozenges, or another formula was counted. A study exposure is not a checkout instruction.

Nor can we halve the amount and call 25 mg an evidence-based PCOS dose. The paper did not compare doses or find the lowest amount that might work.

All of the isolated-zinc PCOS trials we found used zinc sulfate. None compared sulfate with citrate, gluconate, picolinate, bisglycinate, or oxide. There is no evidence-based “best zinc for PCOS” form. Read the label for the elemental amount, then count it across every product you use.

High zinc intake can reduce copper absorption, but that does not create a universal copper-to-zinc ratio. Adding copper by formula does not make an unsupported zinc dose sensible. The decision still depends on the reason for taking zinc, total intake, duration, and whether monitoring is needed.

Before zinc becomes the answer

A PCOS/PMOS diagnosis does not diagnose zinc deficiency. Low intake is more plausible in some contexts, including restrictive diets, gastrointestinal disorders, bariatric surgery, pregnancy, and lactation. That is a separate question from whether 50 mg improves an androgen-related symptom.

Pregnancy also raises zinc requirements without turning the study dose into a pregnancy protocol. Count the zinc in a prenatal before adding another product. Zinc can interact with quinolone and tetracycline antibiotics and penicillamine, and some diuretics affect zinc status. Supplemental iron can also affect zinc absorption. If one of those applies, take the exact product labels to the clinician or pharmacist managing the medication or pregnancy rather than improvising the timing.

The practical distinction is simple: correcting inadequate zinc intake is one decision; using high-dose zinc to treat a PCOS symptom is another. The second currently rests on a flagged paper with a conflicted design record.

Why I am not using the metabolic claims

The paper that reported symptom outcomes is not the only isolated-zinc PCOS study. Earlier short trials examined inflammatory or metabolic markers rather than androgen-related symptoms. Foroozanfard and colleagues' 2015 metabolic paper is now accompanied by a formal Foroozanfard et al. 2015 concern record, so I am not using its positive results to sell a broader zinc benefit.

In searches of PubMed and ClinicalTrials.gov through September 2, 2026, we did not find a newer published isolated-zinc human PCOS intervention trial. Combination products cannot tell us what zinc did on its own.

The evidence problem is not just the small samples. The two papers most likely to support broad PCOS zinc claims now carry formal publisher concerns. Zinc is still an essential nutrient. That is not the same thing as a zinc treatment protocol for PCOS/PMOS.